Patents Assigned to Research Corporation Technologies, Inc.
  • Patent number: 7745200
    Abstract: The present invention provides formaldehyde dehydrogenase genes (FLD) from methylotrophic yeasts. The FLD structural genes confer resistance to formaldehyde and are therefore useful as a selectable marker in methylotrophic yeasts. The FLD promoter sequences are strongly and independently induced by either methanol as sole carbon source (with ammonium sulfate as nitrogen source) or methylamine as sole nitrogen source (with glucose as carbon source). Induction under either methanol, methylamine or both provides levels of heterologous gene expression comparable to those obtained with the commonly used alcohol oxidase I gene promoter (PAOX1). The FLD promoter of Pichia pastoris (PFLD1) is an attractive alternative to PAOX1 for expression of foreign genes in P. pastoris, allowing regulation by carbon (methanol) or nitrogen (methylamine) source within the same expression strain.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: June 29, 2010
    Assignee: Research Corporation Technologies, Inc.
    Inventor: James M. Cregg
  • Publication number: 20090263863
    Abstract: The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided.
    Type: Application
    Filed: February 11, 2009
    Publication date: October 22, 2009
    Applicants: VIB, VZW, UNIVERSITEIT GENT, RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Roland Contreras, Nico L. M. Callewaert, Wouter Vervecken, Vladimir Kaigorodov
  • Publication number: 20090181427
    Abstract: The present invention describes the use of hybrid short 3? untranslated (3?UTR) regions which are composed of two regions, one region from an 3? untranslated region of a stable eukaryotic mRNA, and another region from the downstream end of an 3? untranslated region of another eukaryotic mRNA that contains a polyadenylation (polyA) signal. The use of such hybrid regions allows for an efficient protein expression when used in conjunction with circular or linear expression DNA molecules. The present invention provides a recombinant DNA that is composed of a promoter, a protein coding region, and the hybrid 3?UTR in a continuous and directional orientation. The efficient expression systems of the invention are suitable for the economical and efficient production of therapeutic proteins and for use with both transient and stable expression systems.
    Type: Application
    Filed: December 12, 2005
    Publication date: July 16, 2009
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventor: Khalid S. Abu Khabar
  • Publication number: 20090105591
    Abstract: A method and system for imaging a sample. The method includes the steps of generating an ultrasonic signal, directing the signal into a sample, which signal is distorted and contains a first order and higher order component signals at first and higher frequencies respectively. The received distorted signal is processed, and an image is formed, and then displayed, from the sum of the first order and second order component signals of the received distorted signal.
    Type: Application
    Filed: December 24, 2008
    Publication date: April 23, 2009
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventor: Ted Christopher
  • Patent number: 7507573
    Abstract: The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: March 24, 2009
    Assignees: VIB, vzw, Universiteit Gent, Research Corporation Technologies, Inc.
    Inventors: Roland Contreras, Nico L. M. Callewaert, Wouter Vervecken, Vladimir Kaigorodov
  • Publication number: 20070298500
    Abstract: The present invention provides formaldehyde dehydrogenase genes (FLD) from methylotrophic yeasts. The FLD structural genes confer resistance to formaldehyde and are therefore useful as a selectable marker in methylotrophic yeasts. The FLD promoter sequences are strongly and independently induced by either methanol as sole carbon source (with ammonium sulfate as nitrogen source) or methylamine as sole nitrogen source (with glucose as carbon source). Induction under either methanol, methylamine or both provides levels of heterologous gene expression comparable to those obtained with the commonly used alcohol oxidase I gene promoter (PAOX1). The FLD promoter of Pichia pastoris (PFLD1)is an attractive alternative to PAOX1 for expression of foreign genes in P. pastoris, allowing regulation by carbon (methanol) or nitrogen (methylamine) source within the same expression strain.
    Type: Application
    Filed: June 4, 2007
    Publication date: December 27, 2007
    Applicant: Research Corporation Technologies, Inc.
    Inventor: James Cregg
  • Patent number: 7250502
    Abstract: The present invention provides formaldehyde dehydrogenase genes (FLD) from methylotrophic yeasts. The FLD structural genes confer resistance to formaldehyde and are therefore useful as a selectable marker in methylotrophic yeasts. The FLD promoter sequences are strongly and independently induced by either methanol as sole carbon source (with ammonium sulfate as nitrogen source) or methylamine as sole nitrogen source (with glucose as carbon source). Induction under either methanol, methylamine or both provides levels of heterologous gene expression comparable to those obtained with the commonly used alcohol oxidase I gene promoter (PAOX1). The FLD promoter of Pichia pastoris (PFLD1) is an attractive alternative to PAOX1 for expression of foreign genes in P. pastoris, allowing regulation by carbon (methanol) or nitrogen (methylamine) source within the same expression strain.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: July 31, 2007
    Assignee: Research Corporation Technologies, Inc.
    Inventor: James M. Cregg
  • Publication number: 20070142297
    Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
    Type: Application
    Filed: January 10, 2007
    Publication date: June 21, 2007
    Applicant: Research Corporation Technologies, Inc.
    Inventor: Robert Harris
  • Patent number: 7186859
    Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: March 6, 2007
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris
  • Patent number: 7153661
    Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: December 26, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 7148378
    Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: December 12, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris
  • Patent number: 7119171
    Abstract: The present invention provides modified fibronectin type III (Fn3) molecules, nucleic acid molecules encoding the modified Fn3 molecules, and related vectors and host cells.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: October 10, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 7104956
    Abstract: A method and system for imaging a sample. The method includes the steps of generating an ultrasonic signal, directing the signal into a sample, which signal is distorted and contains a first order and higher order component signals at first and higher frequencies respectively. The received distorted signal is processed, and an image is formed, and then displayed, from one of the higher order component signals of the received distorted signal.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: September 12, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Ted Christopher
  • Patent number: 7078490
    Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding a monobody, and a variegated nucleic acid library encoding a monobody, are provided by the invention. Also provided are methods of preparing an Fn3 polypeptide monobody, and kits to perform such methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: July 18, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohel Koide
  • Patent number: 7030099
    Abstract: A DNA comprising a 609 bp base sequence from ?559 to +50 when the first base sequence of exon 1 of the midkine gene, a human retinoic acid-responsive growth/differentiation factor was set as +1, or a DNA comprising a 251 bp base sequence from ?213 to +38 when the transcription initiation point of the c-erbB-2 gene belonging to the EGF receptor family and having a tyrosine kinase activity was set as +1 has a tumor-specific transcription activity, and the promoter activity thereof is high, and therefore is very important as a tumor-specific promoter for use in the suicide gene therapy that combines the use of a gene for a drug metabolizing enzyme and a prodrug for cancer therapy, the gene therapy of cancer using an expression vector that contains a gene encoding a cytokine, and the gene therapy of cancer using an oncolytic virus.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: April 18, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Masatoshi Tagawa
  • Patent number: 7011831
    Abstract: Fabry disease results from an X-linked deficiency in the enzyme ?-galactosidase A. The present invention is directed to recombinant human ?-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of ?-galactosidase A are also provided.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: March 14, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David Hudgins Calhoun, George Coppola
  • Patent number: 7004905
    Abstract: A method and system for imaging a sample. The method includes the steps of generating an ultrasonic signal, directing the signal into a sample, which signal is distorted and contains a first order and higher order component signals at first and higher frequencies respectively. The received distorted signal is processed, and an image is formed, and then displayed, from one of the higher order component signals of the received distorted signal.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: February 28, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Ted Christopher
  • Patent number: 6906054
    Abstract: The invention provides pharmaceutical compositions comprising compounds of formula I and IV: wherein R1-R11 and A have any of the values defined in the specification, and their pharmaceutically acceptable salts. The pharmaceutical compositions are useful for inhibiting ?-lactamase enzymes, for enhancing the activity of ?-lactam antibiotics, and for treating ?-lactam resistant bacterial infections in a mammal.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: June 14, 2005
    Assignee: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, A. Srinivasa Rao, Greg C. Adam, Sirishkumar D. Nidamarthy, Venkata Ramana Doppalapudi
  • Patent number: 6884910
    Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: April 26, 2005
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris
  • Patent number: RE38947
    Abstract: A chiral catalyst is disclosed together with methods of using it for enantioselective syntheses. The chiral catalyst includes a nucleus with two metal atoms that has four bridging ligands oriented radially to the axis of the nucleus. Each of these ligands includes a two complexing atoms each complexed to one of the metal atoms. At least one of the bridging ligands includes a chiral center which is bonded to one of the complexing atoms. Preferably, all four of the bridging ligands include a chiral center bonded to one of the complexing atoms. The catalyst of the invention has been found to be useful in catalyzing carbenoid transformation reactions such as cyclopropanation.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: January 24, 2006
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Michael P. Doyle